diabetic retinopathy — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T7042	1,5-Isoquinolinediol		PARP
	1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM). The poly(ADP-ribose) polymerases (PARPs) form a family of enzymes with roles in DNA repair and apoptosis. 1, 5-Isoquinolinediol...		PARP
T3803	Specnuezhenide	Nuzhenide,Nuezhenide	Others , NF-κB , Wnt/beta-catenin
	Specnuezhenide (Nuezhenide) significantly protects human neuroblastoma SH-SY5Y cells from 6-hydroxydopamine-induced neurotoxicity.Nuezhenide is the main inhibitory compound of fruits, it shows a clear inhibitory effect t...		Others , NF-κB , Wnt/beta-catenin
T25340	Diprotin A	Ile-Pro-Ile	DPP-4
	Diprotin A (Ile-Pro-Ile) (Ile-Pro-Ile) is a dipeptidyl peptidase IV (DPP-IV) inhibitor.		DPP-4
T36196	CAY10746		ROCK
	CAY10746 is a selective Rho kinase (ROCK) inhibitor that inhibits ROCK I and ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively.CAY10746 can be used to study diabetic retinopathy.		ROCK
T26326	VU0285655-1	VU-0285655,VU0285655,BML 280,VU 0285655,BML280,BML-280	TNF , Phospholipase , Interleukin
	VU0285655-1(BML-280) is a potent and selective phospholipase D2 (PLD2) inhibitor that inhibits the proliferation of PLD2-deficient cells.VU0285655-1 has an inhibitory effect on high glucose-induced caspase-3 cleavage and...		TNF , Phospholipase , Interleukin
T4S0969	Obtusifolin		Antioxidant , NF-κB
	1. Obtusifolin has antioxidant properties and improves chemically induced diabetes and its complications by modulation of oxidative stress. 2. Obtusifolin suppresses phthalate esters-mediated bone resorption, thus may be...		Antioxidant , NF-κB
T23757	Ascorbic acid, rutoside drug combination	Rutinoscorbin,Rutascorbin,Ruta C 60,Cerutin
	Ascorbic acid, rutoside drug combination is used for treating diabetic retinopathy.
T61403	Plasma kallikrein-IN-3
	Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].
T27670	JNJ-26076713	JNJ26076713
	JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.
TN5942	Dammarenediol II	Dammar-24-ene-3,20-diol
	Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabetic retinopathy, it can inhibit vascular endothelial growth factor (VEGF)-induced intracellular reactive oxygen specie...
T72337	Plasma kallikrein-IN-2
	Plasma kallikrein-IN-2, a potent inhibitor of plasma kallikrein (PKal) with an inhibitory concentration (IC) 50 value of 0.1 nM, is utilized in research targeting hereditary angioedema, diabetic macular edema, and diabet...
T79059	CXCR4-IN-1		CXCR
	CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic retinopathy, and inflammation [1].		CXCR
T74867	UBX1325
	UBX1325, a Bcl-xL inhibitor, enhances apoptosis in senescent cells, serving as an effective anti-aging agent. It holds potential for age-related eye disease research, including diabetic macular oedema (DME), age-related ...
T82663	CU06-1004	Sac-1004
	CU06-1004 (Sac-1004) is an orally active compound that acts as an endothelial dysfunction blocker. It mitigates endothelial dysfunction by inhibiting hyperpermeability and inflammation. The compound demonstrates efficacy...